In the 2026 China PIII, Akeso ranked 5th in Innovation and 9th in Invention. In 2025, leveraging its proprietary bispecific antibody technology platform, the company continued to advance core product commercialization, late-stage clinical development and overseas registration, progressively building an innovation system centered on first-in-class bispecific technology, with domestic commercialization and global clinical development advancing in synergy.

Commercial growth of its core bispecific antibodies provided support for Akeso's continued innovative R&D. In 2025, the company recorded total revenue of approximately RMB 3.056 billion, up 43.9% YoY, of which commercial sales revenue was approximately RMB 3.033 billion, up 51.5% YoY, driven mainly by the NRDL listing and expanded market coverage of cadonilimab (Kaitanni®) and ivonescimab (Yidafang®), as well as sales contributions from newly approved first-line indications. R&D expenditure for the period was approximately RMB 1.575 billion, up 32.6% YoY, continuing to support indication expansion of core products and the development of novel antibody drugs...

Download the report to read the full company profile.